Results from the PSMAddition trial were published in a phase 3 setting and showed several clear numbers worth noting. The trial compared standard double hormone-based treatment alone (ADT + ARPI) versus the same treatment plus a PSMA-targeted radioligand therapy (Pluvicto), in men with metastatic hormone-sensitive prostate cancer.The biggest headline was a 58% lower risk of […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! As you can probably tell, every now and then I blow off steam by generating images with AI! This week we have quite a few updates on the clinical trial front, as well as some interesting insights from preclinical […]
The ARASEC trial, offers compelling evidence for darolutamide combined with androgen deprivation therapy as a treatment option for men with metastatic hormone-sensitive prostate cancer. This Phase 2 study tackled a challenging ethical dilemma in modern clinical trial design: how to evaluate a new treatment when randomizing patients to receive only standard ADT would be considered […]
Telmisartan, a widely used blood pressure drug, has shown unexpected promise as a booster for cancer treatment. Preclinical research indicates that when telmisartan is combined with the PARP inhibitor olaparib, cancer cells accumulate more DNA damage and become more vulnerable to treatment, even if they do not carry the usual BRCA‑type DNA repair defects that […]
There is a new flexible trial for men with metastatic prostate cancer that has stopped responding to hormone therapy. Phase 1/2 PROSPECTOR trial tests three options: a PSMA‑targeted radioactive drug (AZD2265), the same drug combined with a PARP1 inhibitor (AZD9574), and standard docetaxel chemotherapy. The first part of the trial finds safe dose levels and […]
GTB-5550 has begun Phase 1 clinical testing in solid tumors, marking the first patient dosing in a dose-escalation basket study. The trial is starting with prostate cancer, a setting where B7-H3 is reportedly highly expressed and where treatment options remain limited in the metastatic castration-resistant stage. The therapy is being delivered subcutaneously, which is notable […]
INR731 is an oral, investigational anticancer drug now entering first‑in‑human testing for men with metastatic castration‑resistant prostate cancer (mCRPC). It is being evaluated in a global, open‑label Phase 1 study with the primary goal of defining its safety, tolerability, pharmacokinetics, pharmacodynamics, and a recommended dose for further development, rather than demonstrating efficacy at this stage. […]
GDC‑1261 is a new study drug being tested in men with advanced or metastatic prostate cancer in a first‑in‑human Phase 1/2 trial. The public description of the study states that the main goals are to evaluate the safety profile, pharmacokinetics, and preliminary anti‑tumor activity of GDC‑1261 and to identify a recommended dose and dosing schedule […]
Cancer drugs often fail not because they are weak, but because they never reach the exact place they are supposed to act, all the way down to the tiny structures inside tumour cells. Researchers at the National University of Singapore have developed a new way to search for nanoparticles that can carry treatment directly to […]
The updated Phase 1/2 data for concurrent enzalutamide plus cabazitaxel in chemo‑naïve mCRPC show deep biochemical responses and a promising signal for progression‑free outcomes, but the dataset remains hypothesis‑generating. In a multi‑institutional single‑arm trial of enzalutamide with cabazitaxel (plus prednisone), 35 patients were included in the efficacy analysis with a median follow‑up of 23.7 months; […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy